Halobetasol Propionate (CAS 66852-54-8)
QUICK LINKS
Halobetasol Propionate is a compound explored extensively in the field of dermatological research. Its high potency and anti-inflammatory properties make it a focal point for studies on skin inflammation and the mechanisms by which inflammation can be modulated at the cellular level. Researchers are interested in the compound′s ability to inhibit the production of cytokines and chemokines, which are critical mediators in the inflammatory process. In addition, Halobetasol Propionate is used to study the proliferation and differentiation of keratinocytes, cells that make up a large part of the epidermal layer in the skin. Its effects on various signaling pathways, such as those involving mitogen-activated protein kinases (MAPKs), are also a subject of investigation, as these pathways play a role in cellular responses to external stressors.
Halobetasol Propionate (CAS 66852-54-8) References
- Topical halobetasol propionate in the treatment of plaque psoriasis: a review. | Rivera, AM. and Hsu, S. 2005. Am J Clin Dermatol. 6: 311-6. PMID: 16252930
- Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. | Yawalkar, S., et al. 1991. J Am Acad Dermatol. 25: 1137-44. PMID: 1757603
- Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream. | Bhatia, ND., et al. 2018. J Clin Aesthet Dermatol. 11: 15-19. PMID: 30588269
- A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis. | Radonjic, A. and Evans, EL. 2019. Dermatol Ther. 32: e12979. PMID: 31155813
- Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. | Ramachandran, V., et al. 2020. Ann Pharmacother. 54: 872-878. PMID: 32126800
- Halobetasol propionate for the management of psoriasis. | Bagel, J., et al. 2020. Cutis. 105: 92-96;E4. PMID: 32186526
- Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. | Lebwohl, MG., et al. 2021. Dermatol Ther (Heidelb). 11: 1157-1174. PMID: 34106439
- Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential. | Laquer, V., et al. 2022. JAAD Int. 6: 13-19. PMID: 34870246
- Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis. | Guenther, L., et al. 2021. Skin Therapy Lett. 26: 1-3. PMID: 34871475
- Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses. | Abduelmula, A., et al. 2022. Skin Therapy Lett. 27: 1-4. PMID: 35533304
- Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis. | Bagel, J., et al. 2022. Cutis. 109: 103-109. PMID: 35659807
- A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis. | Chung, M., et al. 2022. Expert Rev Clin Immunol. 18: 997-1003. PMID: 35930002
- Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion. | Kircik, L., et al. 2023. J Clin Aesthet Dermatol. 16: 21-26. PMID: 36950046
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Halobetasol Propionate, 10 mg | sc-211578 | 10 mg | $282.00 |